Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses.
The protective effect of lansoprazole, a new proton pump inhibitor, against aspirin-induced gastric lesions was studied in a double-blind crossover trial with a simultaneous measure of the functional capacities of the mucosal barrier (by a recording of the gastric potential difference) and of the morphologic changes in the mucosa (by gastric endoscopy). After 1 week of treatment with lansoprazole (30 mg per day) or placebo, each healthy volunteer received 1 gm aspirin by mouth. Recording of the gastric potential difference lasted for 3 hours and was followed by gastric endoscopy. Morphologic lesions induced by aspirin were effectively prevented by lansoprazole: Lanza score was 0.67 +/- 0.98 (mean +/- SD) versus 2.25 +/- 1.1 with placebo (p < 0.005, ANOVA). Conversely, the decrease in the gastric potential difference was similar. The inhibition of acid secretion induced by lansoprazole was therefore sufficient to prevent aspirin-induced mucosal lesions without reinforcing the defense capacities of the mucosa. This simple pharmacologic model makes it possible to simultaneously evaluate the functional and morphologic effects of aspirin intake on the gastric mucosa.
Bergmann
J F
JF
Therapeutics Research Unit, Lariboisière Hospital, Paris, France.
Chassany
O
O
Simoneau
G
G
Lemaire
M
M
Segrestaa
J M
JM
Caulin
C
C
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000704:Analysis of Variance; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001241:Aspirin / Q000037:antagonists & inhibitors*; D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D005773:Gastroscopy; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D012016:Reference Values; D013276:Stomach Ulcer / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole; D001241:Aspirin